Jupiter Acquisition (NASDAQ:JAQC) announced that it intends to reconvene and then adjourn today’s shareholder meeting without conducting any business until Dec. 18 at noon Eastern Time.
Shareholders are expected to vote on a proposal to combine with Filament Health, a natural psychedelic drug development company focused on the treatment of substance use disorders.
The deal values Filament at an equity value of approximately $176 million, and had been expected to close by the end of this year, subject to shareholder approvals and other closing conditions.
Jupiter initially planned to hold a vote this month on a deadline extension that would give it until June 2024 to close the deal. Read more.
